Changes of Serum PSA after Alpha Adrenergic Blocker Treatment in Patients with BPH.
- Author:
Jae Hyuk SHIN
1
;
Moon Mok OH
Author Information
1. Department of Urology, Sung Ae General Hospital, Seoul, Korea. urolomm@korea.com
- Publication Type:Original Article
- Keywords:
Prostatic hyperplasia;
Prostate-specific antigen
- MeSH:
Adrenergic Antagonists*;
Biopsy;
Humans;
Incidence;
Lower Urinary Tract Symptoms;
Physical Examination;
Prostate;
Prostate-Specific Antigen;
Prostatic Hyperplasia;
Prostatic Neoplasms;
Ultrasonography
- From:Korean Journal of Urology
2003;44(6):545-549
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To find if the alpha adrenergic blocker, terazosin, changes the PSA in BPH patients. MATERIALS AND METHODS: Patients with a PSA level over 2.5ng/ml, who visited our hospital with lower urinary tract symptoms, were reviewed, and excluded from having prostate cancer (n=101). After a routine check up for BPH, included history taking, a physical examination, laboratory examinations and a transrectal ultrasound, on their first visit, the PSA level and IPSS were checked again after 4 weeks of alpha adrenergic blocker (terazosin) management. RESULTS: The average size of the prostates and age of the patients were 40.6ml and 67.7 years, respectively. Overall, the PSA levels before the treatment was 4.12+/-2.03ng/ml, which decreased significantly, to 3.57+/-1.99ng/ml, after the terazosin treatment (p=0.002). The subgroups, divided by age, prostate size and IPSS score, all showed meaningful declines in the PSA levels, but with no statistical differences. CONCLUSIONS: The results from this research shows that terazosin treatment reduces the PSA levels in BPH patients complaining of lower urinary tract symptoms, and the changes in the pattern of the level may help to differentiate prostatic cancer, and reduce the incidence of a prostatic biopsy.
